

Final Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
21 – 23 October 2014
EB Room, WHO HQ, Geneva

Tuesday, 21 October 2014

Time	Session	Purpose of session, target outcomes and questions for SAGE	
9:00	Welcome - introduction J. Abramson, Chair of SAGE		20 min.
9:10	Report from Director, IVB - Session 1 Global report including key updates and challenges from regions, P. Duclos, WHO, 30 min. Discussion: 50 min	FOR INFORMATION	2h
10:30	Coffee/tea break	Break	30 min.
11:00	Report from Director, IVB - Session 1, (Contd.) Update on the Ebola outbreak and experimental Ebola vaccines, D. Wood, WHO, 15 min. Discussion: 30 min.		
11:40	Report from GAVI - Session 2 Report from the GAVI Alliance, R. Newman, GAVI Alliance, 20 min. Discussion: 20 min.	FOR INFORMATION	40 min.
12:20	Reports from other Advisory Committees on Immunization - Session 3 Report of the Global Advisory Committee on Vaccine Safety (GACVS), M. Wharton, Chair of GACVS, 10 min. Discussion: 10 min. Report of the Immunization Practices Advisory Committee (IPAC), C. Morgan,	FOR INFORMATION	1h 20 min.

	Chair of IPAC, 10 min. Discussion: 10 min.		
13:00	Lunch	Break	1h
14:00	Reports from other Advisory Committees on Immunization - Session 3, (Contd.) Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC), R. Breiman, Chair of IVIR-AC, 10 min. Discussion: 10 min. Report on the first meeting of the Product Development for Vaccines Advisory Committee (PDVAC), D. Kaslow, Chair of PDVAC, 10 min. Discussion: 10 min. Report of the Expert Committee on Biological Standardization (ECBS), E. Griffiths, Chair of ECBS, 10 min. Discussion: 10 min.	FOR INFORMATION	
15:00	GVAP progress report - Session 4 The GVAP Secretariat Report 2014: Update on process, new indicators, & dashboard, T. Cherian (For the Secretariat of the Decade of Vaccines Working Group), WHO, 15 min. Summary of GVAP implementation progress review and recommendations for corrective actions, N. Arora, Chair of the SAGE Decade of Vaccines Working Group, 30 min.	FOR DISCUSSION AND DECISION SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan. Specially, SAGE will be asked to: <ul style="list-style-type: none"> • Review the DoV WG "Assessment report on DoV progress" based on the "GVAP Secretariat report 2014" and some Independent stakeholder submissions. • Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection. • Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed. • Provide recommendations and corrective actions for Members States, regions, partners, donor agencies "SAGE Assessment report on the Decade of Vaccines progress" which will be the basis of the "progress report" for the WHO Executive Board and World Health Assembly. 	2h
15:45	Coffee/tea break	Break	30 min.

16:15	GVAP progress report - Session 4 (Contd.) Discussion: 1h 15 min.	FOR DISCUSSION AND DECISION	
17:30	Cocktail		

Wednesday, 22 October 2014

08:30	Japanese Encephalitis vaccines - Session 5 Introduction of the topic, objectives of the session and background on Japanese encephalitis, P. Tharmaphornpilas, Chair of the SAGE working group on Japanese encephalitis vaccines, 10 min. Vaccines available against JE, A. Barrett, Member of the SAGE working group on Japanese encephalitis vaccines, 10 min. Review of the evidence: vaccine immunogenicity, effectiveness, and co-administration, S. Hills, Member of the SAGE working group on Japanese encephalitis vaccines, 15 min. Review of the evidence: vaccine safety and other evidence review, H. Meyer, Member of the SAGE working group on Japanese encephalitis vaccines, 15 min. Discussion: 30 min. Review of proposed recommendations on Japanese encephalitis vaccines, P. Tharmaphornpilas, Chair of the SAGE working group on Japanese encephalitis vaccines, 10 min. Discussion: 30 min.	FOR DECISION Present SAGE with the report of the SAGE working group on Japanese encephalitis vaccines and request SAGE's endorsement of the proposed recommendations. Discuss data gaps and research needs. Review the immunogenicity, effectiveness and safety profile of Japanese encephalitis vaccines and proposed schedules, including booster requirements and co-administration with other vaccines. SAGE recommendations on vaccine use will then be used to update the 2006 WHO position paper on the use of Japanese encephalitis vaccines.	2h
10:30	Coffee/tea break	Break	30 min.

11:00	<p>Meningococcal A conjugate vaccine impact and routine immunization schedule in infants and young children - Session 6</p> <p>Why are we reviewing the evidence on meningococcal A conjugate vaccine and what are the questions for SAGE today? K. O'Brien, SAGE member, 5 min.</p> <p>Rollout of the meningococcal A conjugate vaccine through mass vaccination campaigns in countries of the meningitis belt, M. Djingarey, WHO, 10 min.</p> <p>Results from clinical trials in infants and young children, safety in pregnancy, and review of routine coverage data, A. Hodgson, Ghana Health Service, 15 min.</p> <p>Modeling of strategies for routine use of the meningococcal A conjugate vaccine, in the context of a dynamic vaccination program, and future evidence needs to inform vaccine policy, C. Trotter, University of Cambridge, 15 min.</p> <p>Questions for clarification: 15 min.</p> <p>What are the preferred schedules for meningococcal A conjugate vaccine for infants and young children living in countries of the African meningitis belt? K. O'Brien, SAGE member, 10 min.</p> <p>Discussion: 50 min.</p>	<p>FOR DECISION</p> <p>What are the preferred schedules for meningococcal A conjugate vaccine in infants and young children living in countries of the African meningitis belt to achieve sustainable disease control following the initial mass vaccination campaigns?</p> <p>This will lead to an update of the meningococcal position paper</p> <p>What are the gaps in policy-oriented information?</p>	2h
13:00	Lunch	Break	1h
14:00	<p>Global polio eradication initiative - Session 7</p> <p>Introduction: Issues for SAGE decisions and discussions, B. Aylward, WHO, 15 min.</p> <p>Major decisions for the OPV2 withdrawal: the report from the Polio Working Group, P. Figueroa, Chair of SAGE Working, 30 min.</p> <p>Discussion: 60 min.</p> <p>Progress towards interruption of wild poliovirus and persistent type 2 cVDPV and risk mitigation strategy, H. Jafari, WHO, 15 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>For decision:</p> <ul style="list-style-type: none"> · Type 2 risk mitigation strategy prior to OPV2 withdrawal · Type 2 risk assessment and response strategy after OPV2 withdrawal · Bio-containment strategy · mOPV2 stockpile policy <p>For discussion:</p> <ul style="list-style-type: none"> · Progress in eliminating wild and persistent cVDPV poliovirus 	3h
16:00	Coffee/tea break		30 min.

16:30	Global polio eradication initiative - Session 7 (Contd.) Type 2 risk assessment and response strategy after OPV2 withdrawal, R. Sutter, WHO, 15 min. Discussion: 15 min. Operationalizing IPV and bOPV introduction in priority countries, M. Zaffran, WHO, 15 min. Discussion: 15 min.		
17:30	End of day		

Thursday, 23 October 2014

08:30	<p>Hepatitis E vaccine - Session 8</p> <p>Introduction, N. Arora, Chair of the SAGE Working Group on hepatitis E vaccine, 5 min.</p> <p>Hepatitis E: epidemiology and disease burden, E. Teshale, Member of the SAGE Working Group on hepatitis E vaccine, 15 min.</p> <p>Questions for clarification: 10 min.</p> <p>Composition, safety, efficacy and immunogenicity of the licensed hepatitis E vaccine, R. Aggarwal, Member of the SAGE Working Group on hepatitis E vaccine, 15 min.</p> <p>Questions for clarification: 10 min.</p> <p>Recommendations of SAGE Working Group the hepatitis E vaccine, N. Arora, Chair of the SAGE Working Group on hepatitis E vaccine, 15 min.</p> <p>General discussion: 50 min.</p>	<p>FOR DECISION</p> <p>Present SAGE with:</p> <ol style="list-style-type: none"> 1. a review of data regarding the global prevalence and burden of disease caused by hepatitis E 2. a review of safety, efficacy, immunogenicity, cost effectiveness and programmatic issues related to the hepatitis E vaccine 3. the hepatitis E vaccine pipeline <p>SAGE will be expected to provide recommendations on the use of hepatitis E vaccine.</p>	2h
10:30	Coffee/tea break	Break	30 min.
11:00	<p>Vaccine hesitancy - Session 9</p> <p>Introduction. J. Eskola, Chair of the SAGE Vaccine Hesitancy Working Group, 10 min.</p> <p>Deliverables and conclusions. N. MacDonald, Member of the SAGE Vaccine Hesitancy Working Group, 25 min.</p> <p>Recommendations. J. Eskola, Chair of the SAGE Vaccine Hesitancy Working Group, 15 min.</p> <p>Discussion: 1h 40 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>SAGE will be presented with and asked to review and discuss the deliverables and conclusions of the Vaccine Hesitancy Working Group including:</p> <ul style="list-style-type: none"> • The definition of hesitancy • The Matrix of determinants of hesitancy • The Results of the immunization managers' survey and a systematic review of the drivers of vaccine hesitancy and their impact • A systematic review of strategies of vaccine hesitancy • The proposed indicators and survey questions • The Landscape of organizations dealing with hesitancy <p>SAGE will be expected to make a decision on the proposed recommendations on how deal with vaccine hesitancy.</p>	2h 30 min.
13:30	Closing		
13:40	End of meeting		